|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:atccode
|
L02 AE01
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Eligard
|
|
gptkbp:class
|
gonadotropin-releasing hormone agonists
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
hormone therapy
|
|
gptkbp:contraindication
|
hypersensitivity to leuprolide
|
|
gptkbp:counseling_services
|
report any severe side effects
|
|
gptkbp:dosage_form
|
30 mg
|
|
gptkbp:drug_interactions
|
may increase blood sugar levels
|
|
gptkbp:duration
|
as directed by physician
|
|
gptkbp:effective_date
|
gptkb:2000
FDA approved
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eligard 30 mg
|
|
gptkbp:incompatibilities
|
do not mix with other medications
|
|
gptkbp:indication
|
advanced prostate cancer
|
|
gptkbp:ingredients
|
gptkb:leuprolide_acetate
|
|
gptkbp:interacts_with
|
anticoagulants
CYP3 A4 inhibitors
|
|
gptkbp:is_monitored_by
|
testosterone levels
|
|
gptkbp:lifespan
|
3 hours
|
|
gptkbp:manufacturer
|
gptkb:Taro_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Eligard
|
|
gptkbp:mechanism_of_action
|
Gn RH agonist
|
|
gptkbp:packaging
|
single-use vial
|
|
gptkbp:patient_education
|
inform about potential side effects
|
|
gptkbp:patient_population
|
adult men
|
|
gptkbp:pharmacokinetics
|
subcutaneous absorption
decreases testosterone production
|
|
gptkbp:previous_name
|
gptkb:leuprolide_acetate
|
|
gptkbp:price
|
varies by pharmacy
|
|
gptkbp:provides_guidance_on
|
follow oncologist recommendations
|
|
gptkbp:recommissioned
|
requires reconstitution before use
|
|
gptkbp:requires
|
gptkb:true
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:safety
|
not for use in children
not for use in women
|
|
gptkbp:service_frequency
|
every 3 months
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
headache
nausea
insomnia
weight gain
osteoporosis
mood changes
hot flashes
decreased libido
|
|
gptkbp:storage
|
store in refrigerator
|
|
gptkbp:structure
|
C59 H84 N16 O12
|
|
gptkbp:therapeutic_category
|
oncology
|
|
gptkbp:used_for
|
gptkb:Oncology
|
|
gptkbp:website
|
abdomen
|
|
gptkbp:bfsParent
|
gptkb:Eligard
|
|
gptkbp:bfsLayer
|
6
|